Stock HAE HAEMATO AG
Add to a list
To use this feature you must be a member
Log inSign up

Ratings HAEMATO AG Xetra

Equities

HAE

DE000A289VU3

End-of-day quote Xetra
Other stock markets
 06:00:00 2024-02-04 pm EST 		5-day change 1st Jan Change
26.2 EUR -0.76% Intraday chart for HAEMATO AG -1.50% -5.76%
2021 HAEMATO AG Proposes Dividend Payment CI
2021 HAEMATO AG Provides Earnings Guidance for the Year 2021 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company shows low valuation levels, with an enterprise value at 0.34 times its sales.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • This company will be of major interest to investors in search of a high dividend stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company sustains low margins.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HAEMATO AG Stock HAEMATO AG
-5.76% 119M -
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.55% 9.06B
A-
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-12.75% 4.96B
A-
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+42.38% 4.47B -
YUHAN CORPORATION Stock Yuhan Corporation
+5.23% 3.9B
B-
INDIVIOR PLC Stock Indivior PLC
+19.83% 2.41B
B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-19.05% 2.41B
C-
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-28.72% 2.23B -
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+11.13% 2.02B - -
SUPERNUS PHARMACEUTICALS, INC. Stock Supernus Pharmaceuticals, Inc.
+3.94% 1.65B
D+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. HAEK Stock
  4. HAE Stock
  5. Ratings HAEMATO AG